EXECUTIVE ENGAGEMENTS
POOL
4749
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
853
Interactions with Platform & by Email
PARTICIPANTS
142
Unique # Participated
VALIDATIONS
41
Responses Validated*
COMPANIES
12
Responses Validated*
* Login for a full stack data experience
DATE
OCT 2022
TABLES
122
PAGES
178
EDITION
16
PRICE
USD 5450
CODE
MCP-6819
*Engagement stats are ongoing and dynamic
RESEARCH MODULES
EXECUTIVES
HIGHLIGHTS & REPORT INDEX
What`s New for 2023?
» Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
» Global competitiveness and key competitor percentage market shares
» Market presence across multiple geographies - Strong/Active/Niche/Trivial
» Online interactive peer-to-peer collaborative bespoke updates
» Access to our digital archives and MarketGlass Research Platform
» Complimentary updates for one year
Looking Ahead to 2023
The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.
Amid the COVID-19 crisis, the global market for RNA Interference (RNAi) estimated at US$65.7 Billion in the year 2020, is projected to reach a revised size of US$183.3 Billion by 2027, growing at a CAGR of 15.8% over the analysis period 2020-2027. Oncology, one of the segments analyzed in the report, is projected to record a 20.2% CAGR and reach US$83.7 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Ocular Disorders segment is readjusted to a revised 18.7% CAGR for the next 7-year period.
The RNA Interference (RNAi) market in the U.S. is estimated at US$17.7 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$43.9 Billion by the year 2027 trailing a CAGR of 21.3% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 15.3% and 18.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 16.9% CAGR.
In the global Respiratory Disorders segment, USA, Canada, Japan, China and Europe will drive the 15.7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$7 Billion in the year 2020 will reach a projected size of US$19.5 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$28.2 Billion by the year 2027, while Latin America will expand at a 18.5% CAGR through the analysis period.
SELECT PLAYERS
Alnylam Pharmaceuticals, Inc.; Benitec BioPharma; Ionis Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; Qiagen, Inc.; Quark Pharmaceuticals, Inc.; Silence Therapeutics PLC
SEGMENTS
» Therapeutics (Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders, Other Therapeutics) » Application (Drug Discovery & Development, Therapeutics, Other Applications)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » Spain » Russia » and Rest of Europe » Asia-Pacific » Australia » India » South Korea » and Rest of Asia-Pacific » Latin America » Argentina » Brazil » Mexico » and Rest of Latin America » Middle East » Iran » Israel » Saudi Arabia » United Arab Emirates » and Rest of Middle East » and Africa
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Influencer Market Insights |
| World Market Trajectories |
| RNA Interference (RNAi) – Global Key Competitors Percentage Market Share in 2022 (E) |
| Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E) |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| 3. MARKET TRENDS & DRIVERS |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for RNA Interference (RNAi) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for RNA Interference (RNAi) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Drug Discovery & Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Drug Discovery & Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Drug Discovery & Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Ocular Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Ocular Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Ocular Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Respiratory Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Respiratory Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Respiratory Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Liver Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Liver Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Liver Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Neuronal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Neuronal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Neuronal Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Other Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Other Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Other Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
| World RNA Interference (RNAi) Market Analysis of Annual Sales in US$ Million for Years 2012 through 2027 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E) |
| USA Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2012, 2021 & 2027 |
| USA Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2012, 2021 & 2027 |
| CANADA |
| Canada Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2012, 2021 & 2027 |
| Canada Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2012, 2021 & 2027 |
| JAPAN |
| RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E) |
| Japan Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2012, 2021 & 2027 |
| Japan Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2012, 2021 & 2027 |
| CHINA |
| RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E) |
| China Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2012, 2021 & 2027 |
| China Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2012, 2021 & 2027 |
| EUROPE |
| RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E) |
| Europe Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| Europe Historic Review for RNA Interference (RNAi) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for RNA Interference (RNAi) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2021 & 2027 |
| Europe Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2012, 2021 & 2027 |
| Europe Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2012, 2021 & 2027 |
| FRANCE |
| RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E) |
| France Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2012, 2021 & 2027 |
| France Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2012, 2021 & 2027 |
| GERMANY |
| RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E) |
| Germany Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2012, 2021 & 2027 |
| Germany Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2012, 2021 & 2027 |
| ITALY |
| Italy Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2012, 2021 & 2027 |
| Italy Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2012, 2021 & 2027 |
| UNITED KINGDOM |
| RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E) |
| UK Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2012, 2021 & 2027 |
| UK Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2012, 2021 & 2027 |
| SPAIN |
| Spain Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Spain Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Spain 15-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2012, 2021 & 2027 |
| Spain Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Spain Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Spain 15-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2012, 2021 & 2027 |
| RUSSIA |
| Russia Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Russia Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Russia 15-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2012, 2021 & 2027 |
| Russia Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Russia Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Russia 15-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2012, 2021 & 2027 |
| REST OF EUROPE |
| Rest of Europe Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2012, 2021 & 2027 |
| Rest of Europe Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2012, 2021 & 2027 |
| ASIA-PACIFIC |
| RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E) |
| Asia-Pacific Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for RNA Interference (RNAi) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for RNA Interference (RNAi) by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2021 & 2027 |
| Asia-Pacific Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2012, 2021 & 2027 |
| Asia-Pacific Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2012, 2021 & 2027 |
| AUSTRALIA |
| RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2022 (E) |
| Australia Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Australia Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Australia 15-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2012, 2021 & 2027 |
| Australia Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Australia Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Australia 15-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2012, 2021 & 2027 |
| INDIA |
| RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2022 (E) |
| India Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| India Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| India 15-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2012, 2021 & 2027 |
| India Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| India Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| India 15-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2012, 2021 & 2027 |
| SOUTH KOREA |
| South Korea Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| South Korea Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| South Korea 15-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2012, 2021 & 2027 |
| South Korea Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| South Korea Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| South Korea 15-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2012, 2021 & 2027 |
| REST OF ASIA-PACIFIC |
| Rest of Asia-Pacific Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Asia-Pacific Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Asia-Pacific 15-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2012, 2021 & 2027 |
| Rest of Asia-Pacific Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Asia-Pacific Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Asia-Pacific 15-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2012, 2021 & 2027 |
| LATIN AMERICA |
| RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2022 (E) |
| Latin America Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| Latin America Historic Review for RNA Interference (RNAi) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Latin America 15-Year Perspective for RNA Interference (RNAi) by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2021 & 2027 |
| Latin America Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Latin America Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Latin America 15-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2012, 2021 & 2027 |
| Latin America Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Latin America Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Latin America 15-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2012, 2021 & 2027 |
| ARGENTINA |
| Argentina Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Argentina Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Argentina 15-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2012, 2021 & 2027 |
| Argentina Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Argentina Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Argentina 15-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2012, 2021 & 2027 |
| BRAZIL |
| Brazil Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Brazil Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Brazil 15-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2012, 2021 & 2027 |
| Brazil Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Brazil Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Brazil 15-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2012, 2021 & 2027 |
| MEXICO |
| Mexico Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Mexico Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Mexico 15-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2012, 2021 & 2027 |
| Mexico Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Mexico Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Mexico 15-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2012, 2021 & 2027 |
| REST OF LATIN AMERICA |
| Rest of Latin America Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Latin America Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Latin America 15-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2012, 2021 & 2027 |
| Rest of Latin America Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Latin America Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Latin America 15-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2012, 2021 & 2027 |
| MIDDLE EAST |
| RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2022 (E) |
| Middle East Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| Middle East Historic Review for RNA Interference (RNAi) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Middle East 15-Year Perspective for RNA Interference (RNAi) by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2021 & 2027 |
| Middle East Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Middle East Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Middle East 15-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2012, 2021 & 2027 |
| Middle East Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Middle East Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Middle East 15-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2012, 2021 & 2027 |
| IRAN |
| Iran Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Iran Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Iran 15-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2012, 2021 & 2027 |
| Iran Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Iran Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Iran 15-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2012, 2021 & 2027 |
| ISRAEL |
| Israel Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Israel Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Israel 15-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2012, 2021 & 2027 |
| Israel Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Israel Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Israel 15-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2012, 2021 & 2027 |
| SAUDI ARABIA |
| Saudi Arabia Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Saudi Arabia Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Saudi Arabia 15-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2012, 2021 & 2027 |
| Saudi Arabia Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Saudi Arabia Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Saudi Arabia 15-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2012, 2021 & 2027 |
| UNITED ARAB EMIRATES |
| UAE Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UAE Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UAE 15-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2012, 2021 & 2027 |
| UAE Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UAE Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UAE 15-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2012, 2021 & 2027 |
| REST OF MIDDLE EAST |
| Rest of Middle East Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Middle East Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Middle East 15-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2012, 2021 & 2027 |
| Rest of Middle East Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Middle East Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Middle East 15-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2012, 2021 & 2027 |
| AFRICA |
| RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2022 (E) |
| Africa Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Africa Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development, Therapeutics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Africa 15-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics and Other Applications for the Years 2012, 2021 & 2027 |
| Africa Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Africa Historic Review for RNA Interference (RNAi) by Therapeutics - Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Africa 15-Year Perspective for RNA Interference (RNAi) by Therapeutics - Percentage Breakdown of Value Sales for Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders and Other Therapeutics for the Years 2012, 2021 & 2027 |
| IV. COMPETITION |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com